Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone

Contraception

Volumn 85, Issue 2, 2012, Pages 177-184

  Blode, Hartmut ^a   Klipping, Christine ^b   Richard, Frank ^c   Trummer, Dietmar ^a   Rohde, Beate ^a   Diefenbach, Konstanze ^a  

^a BAYER PHARMA AG   (Germany)

^b Dinox BV   (Netherlands)

^c Nycomed GmbH   (Germany)

Author keywords

Bioequivalence; Drospirenone; Ethinylestradiol; Levomefolate calcium; Oral contraceptives

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; DROSPIRENONE PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL PLUS MEFOLATE CALCIUM; ORAL CONTRACEPTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG FORMULATION; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HUMAN; MAXIMUM PLASMA CONCENTRATION; METRORRHAGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TABLET;

ADOLESCENT; ADULT; ANDROSTENES; CALCIUM; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; GLUTAMATES; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84855905624     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2011.05.015     Document Type: Article

References (36)

1. J.L. Simpson, L.B. Bailey, K. Pietrzik, B. Shane, and W. Holzgreve Micronutrients and women of reproductive potential: required dietary intake and consequences of dietary deficiency or excess. Part I - folate, vitamin B12, vitamin B6 J Matern Fetal Neonatal Med 23 2010 1323 1343
2. C. Bower, and F.J. Stanley Dietary folate as a risk factor for neural-tube defects: evidence from a case-control study in Western Australia Med J Aust 150 1989 613 619 (Pubitemid 19193772)
3. A.E. Czeizel, and I. Dudas Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation N Engl J Med 327 1992 1832 1835 (Pubitemid 23003073)
4. J. Mulinare, J.F. Cordero, J.D. Erickson, and R.J. Berry Periconceptional use of multivitamins and the occurrence of neural tube defects JAMA 260 1988 3141 3145
5. R.W. Smithells, S. Sheppard, and C.J. Schorah Possible prevention of neural-tube defects by periconceptional vitamin supplementation Lancet 1 1980 339 340 (Pubitemid 10219521)
6. M.M. Werler, S. Shapiro, and A.A. Mitchell Periconceptional folic acid exposure and risk of occurrent neural tube defects JAMA 269 1993 1257 1261 (Pubitemid 23067428)
7. MRC Vitamin Study Research Group Prevention of neural tube defects: results of the Medical Research Council Vitamin Study Lancet 338 1991 131 137
8. L.D. Botto, C.A. Moore, M.J. Khoury, and J.D. Erickson Neural-tube defects N Engl J Med 341 1999 1509 1519 (Pubitemid 29526355)
9. N.J. Wald, M.R. Law, J.K. Morris, and D.S. Wald Quantifying the effect of folic acid Lancet 358 2001 2069 2073 (Pubitemid 34084836)
10. M. Eichholzer, O. Tonz, and R. Zimmermann Folic acid: a public-health challenge Lancet 367 2006 1352 1361
11. L.E. Daly, P.N. Kirke, A. Molloy, D.G. Weir, and J.M. Scott Folate levels and neural tube defects. Implications for prevention JAMA 274 1995 1698 1702
12. U.S. Preventive Services Task Force Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 150 2009 626 631
13. European Surveillance of Congenital Anomalies (EUROCAT) Folic acid special reports: survey of folic acid policy and practice in European countries - December 2007 [cited 26 Apr 2011]; Available from: http://www.eurocat-network. eu/
14. Centers for Disease Control and Prevention (CDC) Spina bifida and anencephaly before and after folic acid mandate - United States, 1995-1996 and 1999-2000 MMWR Morb Mortal Wkly Rep 53 2004 362 365
15. A. Busby, L. Abramsky, H. Dolk, and B. Armstrong Preventing neural tube defects in Europe: population based study BMJ 330 2005 574 575 (Pubitemid 40380352)
16. Food and Drug Administration Summary minutes: Advisory Committee for Reproductive Health Drugs meeting, December 15, 2003 [cited 26 Apr 2011]; Available from: http://www.fda.gov/ohrms/dockets/ac/03/minutes/4002M1-Final.pdf
17. Y. Lamers, R. Prinz-Langenohl, S. Bramswig, and K. Pietrzik Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age Am J Clin Nutr 84 2006 156 161 (Pubitemid 44699180)
18. C. Sampson-Landers, J. Marr, K. Diefenbach, D. Trummer, R. Lynen, and S. Bart Folate status after 24 weeks' treatment with a folate-fortified version of YAZ Abstract and oral presentation at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists: 2010 May 15-19: San Francisco, CA, USA 2010
19. K. Diefenbach, D. Trummer, F. Ebert, M. Lissy, B. Rohde, and H. Blode Changes in folate levels following a 24-week co-administration of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg Eur J Contracept Reprod Health Care 15 Suppl 1 2010 60 201 [Abstract No. 0097]
20. Y. Lamers, R. Prinz-Langenohl, R. Moser, and K. Pietrzik Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women Am J Clin Nutr 79 2004 473 478 (Pubitemid 41115593)
21. K. Pietrzik, L. Bailey, and B. Shane Folic acid and L-5- methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics Clin Pharmacokinet 49 2010 535 548
22. B.J. Venn, T.J. Green, R. Moser, and J.I. Mann Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study Am J Clin Nutr 77 2003 658 662 (Pubitemid 36258576)
23. B.J. Venn, T.J. Green, R. Moser, J.E. McKenzie, C.M. Skeaff, and J. Mann Increases in blood folate indices are similar in women of childbearing age supplemented with [6S]-5-methyltetrahydrofolate and folic acid J Nutr 132 2002 3353 3355 (Pubitemid 35304243)
24. G. Bachmann, P.J. Sulak, C. Sampson-Landers, N. Benda, and J. Marr Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone Contraception 70 2004 191 198 (Pubitemid 39119980)
25. L. Hernadi, J. Marr, D. Trummer, V. De Leo, and F. Petraglia Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen Contraception 80 2009 18 24
26. W. Koltun, A.W. Lucky, and D. Thiboutot Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial Contraception 77 2008 249 256
27. A.W. Lucky, W. Koltun, and D. Thiboutot A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment Cutis 82 2008 143 150
28. J.M. Maloney, P. Dietze Jr., and D. Watson Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial Obstet Gynecol 112 2008 773 781
29. J.M. Maloney, P. Dietze, and D. Watson A randomized controlled trial of a low dose combined oral contraceptive containing 3 mg drospirenone plus 20 mcg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings, and subject self-assessment J Drugs Dermatol 8 2009 837 844
30. T.B. Pearlstein, G.A. Bachmann, H.A. Zacur, and K.A. Yonkers Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation Contraception 72 2005 414 421 (Pubitemid 41676830)
31. K.A. Yonkers, C. Brown, T.B. Pearlstein, M. Foegh, C. Sampson-Landers, and A. Rapkin Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder Obstet Gynecol 106 2005 492 501 (Pubitemid 41208780)
32. K. Pietrzik, Y. Lamers, S. Bramswig, and R. Prinz-Langenohl Calculation of red blood cell folate steady-state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age Am J Clin Nutr 86 2007 1414 1419 (Pubitemid 350126246)
33. E. Ahn, B. Kapur, and G. Koren Study on circadian variation in folate pharmacokinetics Can J Clin Pharmacol 12 2005 e4 9
34. M. Cronin, I. Schellschmidt, and J. Dinger Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives Obstet Gynecol 114 2009 616 622
35. Centers for Disease Control and Prevention (CDC) Use of supplements containing folic acid among women of childbearing age - United States, 2007 MMWR Morb Mortal Wkly Rep 57 2008 5 8
36. European Surveillance of Congenital Anomalies (EUROCAT) Special Report Prevention of neural tube defects by periconceptional folic acid supplementation in Europe (2009) [cited 26 Apr 2011]; Available from: http://www.eurocat- network.eu/content/Special-Report-NTD-3rdEd-Part-I.pdf